摘要
目的:观察舒格利单抗联合吉西他滨+顺铂(GP)方案治疗非小细胞肺癌(NSCLC)对患者细胞生长因子与肿瘤标志物表达的影响,旨在为临床NSCLC患者的治疗新方案提供科学参考。方法:采用随机数字表法将2022年5月—2023年5月赣州市赣县区人民医院收治的80例NSCLC患者分为对照组和研究组,每组40例。对照组采取GP方案,研究组采取GP方案联合舒格利单抗。对比两组近期疗效、肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)、鳞状细胞癌抗原(SCCA)、细胞角蛋白19片段(Cyfra21-1)]及细胞生长因子[血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)]和不良反应发生情况。结果:研究组客观缓解率高于对照组,差异有统计学意义(P<0.05);两组疾病控制率对比,差异无统计学意义(P>0.05);治疗前,两组CEA、CA125、SCCA、Cyfra21-1、VEGF、bFGF对比,差异均无统计学意义(P>0.05);治疗后,研究组CEA、CA125、SCCA、Cyfra21-1、VEGF、bFGF均低于对照组,差异均有统计学意义(P<0.05);两组不良反应总发生率对比,差异无统计学意义(P>0.05)。结论:与单纯GP方案相比,舒格利单抗联合GP方案可提高NSCLC患者近期疗效,改善肿瘤标志物与细胞生长因子表达,安全性佳。
Objective:To observe the effects of Sugemalimab combined with Gemcitabine+Cisplatin(GP)regimen on the expression of cell growth factors and tumor markers in patients with non-small cell lung cancer(NSCLC),in order to provide scientific reference for the new treatment regimen for clinical NSCLC patients.Method:A total of 80 patients with NSCLC admitted to Ganxian District People's Hospital of Ganzhou City from May 2022 to May 2023 were divided into control group and study group by random number table method,with 40 cases in each group.The control group received GP regimen,and the study group received GP regimen combined with Sugemalimab.The short-term effect,tumor markers[carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),squamous cell carcinoma antigen(SCCA),cytokeratin 19 fragment(Cyfra21-1)]and cell growth factors[vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF)]and the occurrence of adverse reactions were compared between the two groups.Result:The objective remission rate of the study group was higher than that of the control group,the difference was statistically significant(P<0.05).There was no significant difference in disease control rate between the two groups(P>0.05).Before treatment,there were no significant differences in CEA,CA125,SCCA,Cyfra21-1,VEGF and bFGF between the two groups(P>0.05).After treatment,CEA,CA125,SCCA,Cyfra21-1,VEGF and bFGF in study group were lower than those in control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of total adverse reactions between the two groups(P>0.05).Conclusion:Compared with GP regimen alone,Sugemalimab combined with GP regimen can improve the short-term effect of patients with NSCLC,improve the expression of tumor markers and cell growth factors,and have good safety.
作者
龙腾飞
LONG Tengfei(Department of Oncology,Ganxian District People's Hospital of Ganzhou City,Ganzhou 341100,China)
出处
《中国医学创新》
CAS
2024年第33期66-70,共5页
Medical Innovation of China
基金
2023年赣州市指导性科技计划项目(GZ2023ZSF362)。